FACTORS AFFECTING SURVIVAL OF YOUNG CANCER PATIENTS

该项目的总体目标是确定哪些因素会影响 既往诊断为乳腺癌的妇女的复发和死亡风险 45岁。这个项目建立在1400已经收集的信息的基础上 45岁之前被诊断为浸润性乳腺癌的女性 1983-1992年，并就疾病的危险因素进行了访谈。这一群人 将于1996年12月前进行复发率和死亡率的追踪。 这些女性代表了这些事件中的大多数(85%) 在华盛顿州的金县、皮尔斯县和斯诺霍米什县工作多年。 在这个队列中，所有复发和/或死亡的女性都将 已确认身份。这些女性将被与队列中的女性进行比较 无复发和/或死亡，原因如下： 1.详细收集患者特征和危险因素 访谈内容包括口服避孕药使用情况、人工流产史、 和其他生殖因素，乳腺癌家族史， 乳房X光检查病史、肥胖等。 2.手术时机与月经周期有关。 3.组织病理学特征，包括组织学类型，概括性 核级，有丝分裂数，大小，多中心性，位置， 临床表现、淋巴转移和切缘状况 经病理复查确定的肿瘤。 4.用免疫细胞化学方法表达肿瘤相关蛋白，包括 类固醇受体、癌基因蛋白、p53抑癌基因产物、 生长因子和增殖细胞核抗原。 5.通过图像分析确定血管生成反应的证据 血管密度及其基因表达的定量研究 血管生成相关因子。 6.流式细胞仪检测细胞增殖和非整倍体 福尔马林固定的S相比例和DNA含量分析， 石蜡包埋肿瘤。 此外，我们还将评估患者(S)之间的关系 肿瘤的特征和暴露数据(上文1和2) 诊断时的特征(以上3-6项)。

The overall goal of this project is to determine what factors affect the risk of recurrence and death in women diagnosed with breast cancer before age 45. This project builds on the information already collected on 1400 women who were diagnosed with invasive breast cancer before age 45 from 1983 - 1992 and interviewed about risk factors for disease. This cohort will be followed for recurrence and mortality through December, 1996. These women represent the majority (85%) of incident cases from these years in King, Pierce, and Snohomish Counties in Washington State. From within this cohort, all women with recurrence and/or death will be identified. These women will be compared to women from within the cohort without recurrence and/or death on the following factors: 1. Patient characteristics and risk factors collected in the detailed interview such as oral contraceptive use, history of induced abortion, and other reproductive factors, family history of breast cancer, mammography history, obesity, etc. 2. Timing of surgery in relation to the menstrual cycle. 3. Histopathologic characteristics including histologic type, generalized nuclear grade, number of mitoses, size, multicentricity, location, clinical presentation, lymph node metastases, and status of margins of the tumors as determined by pathologic review. 4. Expression of tumor-related proteins by immunocytochemistry, including steroid receptors, oncogene proteins, p53 tumor suppressor gene product, growth factors, and proliferating cell nuclear antigen (PCNA). 5. Evidence of angiogenic response determined by image analysis quantification of vascular density and mRNA expression of angiogenesis-related factors. 6. Cell proliferation and aneuploidy determined by flow cytometric analysis of S-phase fraction and DNA content of formalin-fixed, paraffin-embedded tumor. In addition, we will evaluate the relationship(s) of patient characteristics and exposure data (1 and 2 above) to tumor characteristics (3 - 6 above) at diagnosis.